0136 - CELLULAR IMMUNE PANEL:
The panel identifies the T-lymphocyte populations and calculates the absolute counts. Absolute counts are determined for helper/inducer T lymphocytes (CD4), the suppressor/cytotoxic lymphocytes (CD8) and the total T lymphocytes (CD3). A CD4/CD8 helper/suppressor T-lymphocyte ratio, a CD4/CD3 ratio and a CD8/CD3 ratio are reported. The quantitation of T cell subsets is useful for the evaluation of various immunodeficiency disorders, acquired immunodeficiency disease and evaluation of antiviral therapy.
0138 - CHLAMYDIA TRACHOMATIS CULTURE:
Specimens are plated under centrifugation onto cyclohexamide treated McCoy cell monolayers. Cultures are stained after 48 hours with polyclonal antisera for inclusion bodies characteristic of C. trachomatis.
0182 - HEPATITIS A IgM ANTIBODY, EIA, SERUM:
A positive result indicates recent exposure to HAV. The IgM response will start approximately 2 month after exposure and continues to be measurable for up to 8 months after exposure.
0183 - HEPATITIS B CORE ANTIBODY, EIA, SERUM:
Hepatitis B core antibody (HBcAb) is present in serum after the appearance of hepatitis B surface antigen (HBsAg) and before the appearance of hepatitis B surface antibody (HBsAb). In the absence of HBsAg and HBsAb, HBcAb may be the only serologic marker of recent hepatitis B infection and potentially infectious blood.
0185 - HEPATITIS B SURFACE ANTIGEN, EIA, SERUM:
The hepatitis B surface antigen (HBsAg) is present in acute hepatitis B infection or in chronic carriers of hepatitis B. HBsAg becomes detectable after the incubation stage of the virus that generally lasts 4-12 weeks after exposure.
0186 - HEPATITIS B PANEL, EIA, SERUM:
Panel includes: Hepatitis B Core Antibody, EIA; Hepatitis B Surface Antibody, EIA and Hepatitis B Surface Antigen, EIA.
0187 - HEPATITIS ACUTE PANEL, SERUM:
Panel includes: Hepatitis C Antibody, EIA; Hepatitis B Surface Antigen, EIA and Hepatitis A IgM Antibody, EIA.
0188 - HEPATITIS CUSTOM PANEL, SERUM:
Panel includes: Hepatitis A IgM, EIA; Hepatitis B Core Antibody, EIA; Hepatitis B Surface Antigen, EIA and Hepatitis B Surface antibody, EIA.
0189 - HEPATITIS B SCREENING PANEL, SERUM:
Panel includes: Hepatitis B Surface Antigen, EIA and Hepatitis B Surface Antibody, EIA
0202 - HIV-1 SCREENING ANTIBODY, ELISA, SERUM:
Initial testing is done with ELISA techniques using a whole virus lysate antigen/ synthetic peptides. Positive sera are confirmed using an alternative methodology, i.e., Western blot or IFA.
0203 - HIV-1, PCR, PLASMA, QUALITATIVE:
Centrifuge to separate plasma within 6 hours of draw. Refrigerate to store.
0291 - HIV-1, PCR, PLASMA, QUANTITATIVE:
Also known as.Viral Load Test or HIV-1 RNA PCR. Centrifuge to separate plasma within 6 hours of draw. Refrigerate to store.
0204 - IMMUNOCOMPROMISED VIRAL PANEL, SERUM:
Panel includes: Adenovirus Antibody, CF; Cytomegalovirus IgG and IgM Antibody Panel, IFA; Epstein-Barr Viral Capsid Antigen Antibody Panel, IFA; Herpes simplex, IFA and Varicella-Zoster IgG Antibody, IFA
0239 - POLIOVIRUS ANTIBODY, NEUTRALIZATION, SERUM:
This sensitive procedure is recommended for vaccine response testing and type-specific serodiagnosis of recent Poliovirus infection.
0241 - RABIES EXAMINATION, BIOPSY:
Test includes the fluorescent examination of a specimen smear.
0243 - RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIGEN DETECTION, DFA:
This procedure can detect RSV in specimens taken later that 5 days post onset, when viral isolation becomes increasingly less sensitive due to neutralizing antibodies in respiratory secretions.
0254 - ROTAVIRUS ANTIGEN DETECTION, EIA:
Rotaviruses are the major cause of epidemic viral gastroenteritis in infants and young children worldwide, with peak incidence between mid-December and mid-February. They are also associated with a severe sporadic gastroenteritis of infants and young children.